Report
Hugo Solvet

MEDINCELL | BUY | EUR10

Initiation of a new trial highlights TEVA's strategic commitment
Second asset to reach the clinic as part of the deal with TEVA
Strong expertise validated by TEVA’s commitment
No change to our EUR10 Fair Value
Underlying
Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Hugo Solvet

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch